ReviewBlood advances2023
Deciphering the genetic basis of immune thrombocytopenia: current evidence for genetic predisposition in adult ITP.
Review in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Evaluation ofFrontiers in medicine · 2026Pooled it
- High pretreatment peripheral blood T-cell receptor clonality as a predictor of prolonged response in immune thrombocytopenia.British journal of haematology · 2026Trial
- Increased percentages of circulating T follicular helper cells associate with disease subtype and activity in pediatric immune cytopenias.Haematologica · 2026Article
- An integrative analysis of genetic factors reveals dysregulation of cytokines, immune signaling, and T cell activity as the underlying immune mechanisms in autoimmune immune thrombocytopenia.Thrombosis journal · 2026Article
- Hematological and biochemical markers for predicting severity in COVID-19 patients.BMC infectious diseases · 2026Observational
- When the victim becomes the villain: Platelets as drivers of immune dysregulation in ITP.Journal of translational autoimmunity · 2025Review
- Ubiquitous dysregulation of the Wnt pathway in immune thrombocytopenia genetic susceptibility.Blood vessels, thrombosis & hemostasis · 2025Article
- Assessment of rs1205 and rs1130864 Polymorphisms of C-Reactive Protein Gene (Health science reports · 2025Article
- Primary versus Secondary Immune Thrombocytopenia (ITP): A Meeting Report from the 2023 McMaster ITP Summit.Thrombosis and haemostasis · 2025Article
- Refractoriness to eltrombopag in adult primary immune thrombocytopenia: utility of next-generation sequencing techniques.Blood vessels, thrombosis & hemostasis · 2025Article
- Review
- Heat exposure and pediatric immune thrombocytopenia in Japan from 2011 to 2022: a nationwide space-timestratified case-crossover study.Haematologica · 2025Article
- The intersection of epigenetics and immune thrombocytopenia: new insights into disease mechanisms and treatments.Molecular biology reports · 2025Review
- Case Report: A case of pediatric persistent refractory ITP responsive to avatrombopag.Frontiers in immunology · 2025Article
- The Many Faces of Immune Thrombocytopenia: Mechanisms, Therapies, and Clinical Challenges in Oncological Patients.Journal of clinical medicine · 2024Review
- Immune thrombocytopenic purpura after influenza vaccine administration; a systematic review and meta-analysis.Tropical diseases, travel medicine and vaccines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune thrombocytopenia (ITP) is the consequence of a complex, still incompletely understood immunological dysregulation. Proposed mechanisms include autoantibody-induced platelet destruction, impaired platelet production as well as abnormalities in T-cell immunity, such as T helper cells (Th1) polarization, a high proportion of Th17 cells, and a reduced number of regulatory T cells. Although the etiology of ITP is incompletely understood and considered multifactorial in most cases, genetic variants are thought to play a key role in susceptibility to ITP, especially in persistent or chronic ITP. Efforts are currently underway to uncover possible predisposing genetic factors for the development of ITP. Single-nucleotide polymorphisms and copy number variations have been identified in several immune-related genes, such as cytokine genes, Fcγ receptor genes or T-cell costimulation genes, and have been associated with patients' susceptibility to ITP. However, because of the clinical heterogeneity and low incidence of ITP it remains challenging to perform genetic analyses with sufficiently large sample size within informative patient populations, highlighting the need for collection of well-annotated biomaterials in clinical trials or registry projects. Another significant challenge is to go beyond performing association studies alone and to establish genotype-phenotype associations, thus proving causality between a genetic alteration and ITP pathogenesis. This review summarizes our current knowledge on genetic alterations identified as potential predisposing factors for the development of ITP in adults, thereby addressing signaling pathways considered critical for ITP pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.